Ip Infusion Software India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 17-11-2024
- Paid Up Capital ₹ 1.00 M
as on 17-11-2024
- Company Age 13 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.51 M
as on 17-11-2024
- Revenue 19.80%
(FY 2023)
- Profit 15.03%
(FY 2023)
- Ebitda 19.89%
(FY 2023)
- Net Worth 17.06%
(FY 2023)
- Total Assets 21.06%
(FY 2023)
About Ip Infusion Software India
The Company is engaged in the Information Technology Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1.51 M.
Michimasa Uematsu, Michael Lau, Atsushi Ogata, and One other member serve as directors at the Company.
- CIN/LLPIN
U72200KA2011FTC056799
- Company No.
056799
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
25 Jan 2011
- Date of AGM
30 Jul 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Ip Infusion Software India?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Atsushi Ogata  | Director | 20-Jun-2013 | Current |
| Michimasa Uematsu | Director | 21-May-2019 | Current |
Michael Lau  | Director | 14-Oct-2015 | Current |
Sudarsan Naganathan  | Whole-Time Director | 16-Mar-2017 | Current |
Financial Performance of Ip Infusion Software India.
Ip Infusion Software India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 19.8% increase. The company also saw a substantial improvement in profitability, with a 15.03% increase in profit. The company's net worth Soared by an impressive increase of 17.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ip Infusion Software India?
In 2023, Ip Infusion Software India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Citi Bank N.A. Creation Date: 07 Nov 2019 | ₹1.51 M | Open |
How Many Employees Work at Ip Infusion Software India?
Ip Infusion Software India has a workforce of 303 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ip Infusion Software India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ip Infusion Software India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
